ANTX
NASDAQ
US
AN2 Therapeutics, Inc. - Common Stock
$3.27
▼ $-0.18
(-5.22%)
Vol 412K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$31.2M
ROE
-47.8%
D/E
0.00
Beta
-0.02
52W
$1–$2
Wall Street Consensus
6 analysts · Apr 20260
Strong Buy
0
Buy
3
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
ORMP
Oramed Pharmaceuticals Inc
P/E 2.6
$113.4M
NTHI
NeOnc Technologies Holdings Inc
$198.2M
DERM
Journey Medical Corp
$209.2M
ASRT
Assertio Holdings Inc
$58.2M
LONA
LeonaBio Inc
TTRX
Turn Therapeutics Inc
VRCA
Verrica Pharmaceuticals Inc
$78.9M
AARD
Aardvark Therapeutics Inc
$285.8M
RANI
Rani Therapeutics Holdings Inc
$164.1M
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.24 | $-0.29 | $-0.05 |
| Sep 2025 | $-0.22 | $-0.31 | $-0.09 |
| Jun 2025 | $-0.34 | $-0.21 | +$0.13 |
| Mar 2025 | $-0.26 | $-0.35 | $-0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$12.7M | -$7.5M | -$10.6M | -$6.5M | -$9.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -48.2% | -48.0% | -48.0% | -48.0% | -47.8% | -47.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.67 | 9.67 | 9.67 | 9.67 | 9.33 | 9.33 |
Key Ratios
ROA (TTM)
-43.0%
P/B
0.5
EPS (TTM)
$-1.13
52W High
$1.55
52W Low
$1.01
$1.01
52-Week Range
$1.55
Financial Health
Free Cash Flow
-$6.4M
Cash
$18.0M
As of Sep 30, 2025
How does ANTX compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ANTX valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
0.5
▼
76%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ANTX profitability vs Pharmaceuticals peers
ROE
-47.8%
▲
12%
above
peers
(-54.3%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-43.0%
▼
15%
below
peers
(-37.4%)
vs Peers
vs Industry
In line
ANTX financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
9.3
▲
178%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.0
▼
103%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ANTX fundamentals radar
ANTX
Peer median
Industry
ANTX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANTX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
CHANDA SANJAY
Officer · Feb 20
38000 shs
DAY LUCY O.
Chief Financial Officer · Feb 20
38000 shs
EASOM ERIC
Chief Executive Officer · Feb 20
112250 shs
EIZEN JOSHUA M
Chief Operating Officer · Feb 20
50000 shs
MARKS GILBERT LYNN
Director · Jan 12
11560 shs
MARTIN PATRICIA A
Director · Jan 12
3650 shs
AZIZ KABEER
Director · Jan 12
11560 shs
CHANDA SANJAY
Officer · Jan 06
9251 shs
DAY LUCY O.
Chief Financial Officer · Jan 06
8807 shs
EIZEN JOSHUA M
Officer · Jan 06
24854 shs
Last 90 days
Top Holders
Top 5: 12.52%Almitas Capital LLC
4.12%
$5.4M
Vanguard Group Inc
3.01%
$4.0M
Pfizer Inc
1.99%
$2.6M
Stonepine Capital Managemen…
1.75%
$2.3M
Peapod Lane Capital LLC …
1.65%
$2.2M
As of Dec 31, 2025
Latest News
No related news yet